ライフサイエンスコーパス: donor-specific tolerance

1 ponse, immunosuppressed T cell response, and donor specific tolerance.

2 o resulted in a state of mixed chimerism and donor specific tolerance.

3 thout immunosuppression to assess for robust donor-specific tolerance.

4 sible therapy to prevent TVS is induction of donor-specific tolerance.

5 indicated that the recipients had developed donor-specific tolerance.

6 transient anti-LFA-1 monotherapy resulted in donor-specific tolerance.

7 row transplantation model in order to induce donor-specific tolerance.

8 emonstrated to effectively induce allogeneic donor-specific tolerance.

9 e) results in mixed xenogeneic chimerism and donor-specific tolerance.

10 h to achieve mixed bone marrow chimerism and donor-specific tolerance.

11 e maintenance immunosuppression or to induce donor-specific tolerance.

12 r anergy, is the major mechanism maintaining donor-specific tolerance.

13 afts was used to test for the development of donor-specific tolerance.

14 g mice, although the animals did not develop donor-specific tolerance.

15 (MR1) and human CTLA4Ig were sued to induce donor-specific tolerance.

16 stem cell transplantation (HSCT) can lead to donor-specific tolerance.

17 soform by mAb (anti-CD45RB) reliably induces donor-specific tolerance.

18 encoded allogeneic MHC class I Ag results in donor-specific tolerance.

19 CD28 stimulation-based strategies to induce donor-specific tolerance.

20 S/BM150/sirolimus protocol showed indefinite donor-specific tolerance.

21 promote long-term graft survival and induce donor-specific tolerance.

22 tablishment of long-term mixed chimerism and donor-specific tolerance.

23 performed previously in adult mice to induce donor-specific tolerance across allogeneic and xenogenei

24 induction of mixed allogeneic chimerism and donor-specific tolerance across full MHC barriers.

25 h induction of permanent mixed chimerism and donor-specific tolerance across fully MHC-mismatched all

26 al antibody and CsA resulted in induction of donor-specific tolerance across the MHC barrier without

27 The induction of bone marrow chimerism and donor-specific tolerance after nonlethal conditioning mi

28 x 10(6)) from CD4 mAb-treated rats conferred donor-specific tolerance after transfer into new sets of

29 ccepted a heart allotransplant and displayed donor-specific tolerance also accepted skin grafts from

30 this agent before transplantation can induce donor-specific tolerance and "split tolerance" to renal

31 sess efficacy of immunodepletion and confirm donor-specific tolerance and chimerism.

32 as long been known to be capable of inducing donor-specific tolerance and hence permitting allograft

33 Donor-specific tolerance and immunocompetence of long-te

34 Donor-specific tolerance and immunocompetence were deter

35 t rather spontaneously develop transferable, donor-specific tolerance and linked suppression in vivo.

36 el nonmyeloablative approach that results in donor-specific tolerance and mixed allogeneic chimerism.

37 before transplantation resulted in long-term donor-specific tolerance and prevented GVHD.

38 The chimeric NOD recipients showed donor-specific tolerance and reversal of insulitis.

39 ALS, BM, and sirolimus results in a state of donor-specific tolerance, and multilineage chimerism evo

40 5RB to produce indefinite graft survival and donor-specific tolerance, and this effect is accomplishe

41 Mixed chimerism and donor-specific tolerance are achieved in mice receiving

42 rt illustrate that established mechanisms of donor-specific tolerance are strained during potent immu

43 6 (B6, H-2(b)) heart transplants resulted in donor-specific tolerance associated with long-term survi

44 ed lymphocyte reaction and ELISPOT) revealed donor-specific tolerance before and after transplantatio

45 e approach that achieves mixed chimerism and donor-specific tolerance but has been limited by minimal

46 ion (IUHCTx) is a promising method to induce donor-specific tolerance but the mechanisms of antigen p

47 e discuss new approaches to the induction of donor-specific tolerance by induction of molecular chime

48 ivors were analyzed for in vitro evidence of donor-specific tolerance by mixed leukocyte reaction (ML

49 table mixed hematopoietic cell chimerism and donor-specific tolerance can be established in miniature

50 Donor-specific tolerance can be induced across a discord

51 Xenogeneic donor-specific tolerance can be induced by transplanting

52 e have recently demonstrated that xenogeneic donor-specific tolerance can be induced by transplanting

53 that xenogeneic bone marrow engraftment and donor-specific tolerance can be induced in mice receivin

54 IS-free donor-specific tolerance can be successfully induced wit

55 ite survival of LBNF1 cardiac allografts; 2) donor-specific tolerance can be then transferred by sple

56 This donor-specific tolerance can then be transferred into a

57 Donor-specific tolerance could be adoptively transferred

58 rpose of this study was to determine whether donor-specific tolerance could be detected in T cells wi

59 Over time, a state of donor-specific tolerance develops in which recipients ar

60 Donor-specific tolerance did not develop clinically or i

61 Long-term chimeras developed donor-specific tolerance (donor skin graft survival of m

62 Donor-specific tolerance (DST) is induced after allogene

63 us to achieve mixed allogeneic chimerism and donor-specific tolerance (DST).

64 between some strains of rodents can lead to donor-specific tolerance either spontaneously or after a

65 Chimeras exhibit robust donor-specific tolerance, evidenced by acceptance of ful

66 the future be used as a method of increasing donor-specific tolerance following IUHCT.

67 ssociation between hemopoietic chimerism and donor-specific tolerance for allografts has been recogni

68 le for up to 2 years and was associated with donor-specific tolerance for renal transplantation.

69 fter bone marrow transplantation may provide donor-specific tolerance for solid organ allografts.

70 In animal models, mixed chimerism confers donor-specific tolerance for solid-organ and cellular gr

71 Furthermore, donor-specific tolerance from anti-LFA-1-treated animals

72 nt) resulted in long term graft survival and donor-specific tolerance in 30 to 50% of the recipients.

73 term pancreatic islet allograft survival and donor-specific tolerance in a mouse model.

74 ally applicable 35-day protocol that induces donor-specific tolerance in a rat hindlimb-transplantati

75 of CTLA4Ig induced long-term engraftment and donor-specific tolerance in all three groups of recipien

76 ixed hematopoietic chimerism leads to stable donor-specific tolerance in allogeneic and closely relat

77 tation can be an effective way for inducting donor-specific tolerance in allogeneic recipients.

78 Ab to promote mixed xenogeneic chimerism and donor-specific tolerance in B6 mice receiving anti-CD8,

79 r data suggest that this approach may induce donor-specific tolerance in clinical islet transplantati

80 MLR and skin grafting confirmed donor-specific tolerance in euthymic recipients.

81 ately predict the development or presence of donor-specific tolerance in humans after transplantation

82 macrochimerism is frequently associated with donor-specific tolerance in many experimental animals an

83 t to inhibit T1D development and also induce donor-specific tolerance in NOD recipients.

84 ow chimerism has been demonstrated to confer donor-specific tolerance in nonsensitized recipients, bu

85 f thymus was imperative for the induction of donor-specific tolerance in rat hind-limb composite tiss

86 shown promise as agents capable of inducing donor-specific tolerance in rodents.

87 ell transplantation has been shown to induce donor-specific tolerance in small-animal models.

88 arrow cell (BMC) engraftment, chimerism, and donor-specific tolerance in the absence of the side effe

89 s in in vivo cytotoxicity assays, suggesting donor-specific tolerance in the innate immune cells was

90 istration of CsA and ALS for 21 days induced donor-specific tolerance in the recipients of the rat hi

91 servations are relevant to the mechanisms of donor-specific tolerance in this patient group.

92 te reaction (MLR) and skin grafting assessed donor-specific tolerance in vitro and in vivo, respectiv

93 Mixed lymphocyte reaction for donor-specific tolerance in vitro was tested at day 160

94 r chimerism was established by TDBMT induced donor-specific tolerance in vivo and in vitro.

95 etermine the level of chimerism and possible donor-specific tolerance, in addition to possible GVHD.

96 r understanding of the processes that govern donor-specific tolerance increases, so must our understa

97 Donor-specific tolerance induced by BMC prevented allogr

98 Donor-specific tolerance induced by bone marrow transpla

99 infiltrating host cells, and the spontaneous donor-specific tolerance induced by liver but not heart

100 d the efficacy of CD4-targeted therapy, with donor-specific tolerance induced in approximately 50% of

101 ation to allow permanent mixed chimerism and donor-specific tolerance induction can be overcome by th

102 Therefore, in addition to focusing on donor-specific tolerance induction, strategies aiming at

103 e endogenous superantigens demonstrated that donor-specific tolerance is due mainly to an intrathymic

104 To examine them for donor-specific tolerance, long-term unresponsive (>120 d

105 oal in transplantation is the achievement of donor-specific tolerance, minimizing the use of immunosu

106 esults in permanent engraftment (>250 d) and donor-specific tolerance not observed previously in this

107 To study the effects of donor-specific tolerance on chronic rejection, we perfor

108 , anti-CD8 mAb administration did not induce donor-specific tolerance or cause nonspecific immune sup

109 The induction of donor-specific tolerance remains a major goal in the fie

110 gulated within allografts of mice displaying donor-specific tolerance, that recruitment of Foxp3-expr

111 We developed an efficient donor-specific tolerance therapy that utilizes infusions

112 Donor-specific tolerance through establishing mixed chim

113 m mixed hematopoietic chimerism and systemic donor-specific tolerance through peripheral and central

114 ts establish a less toxic method of inducing donor-specific tolerance, thus increasing the potential

115 These data demonstrated that donor-specific tolerance to all components of the VCA ca

116 Permanent donor-specific tolerance to allografts is the goal of tr

117 orm by mAb (anti-CD45RB) effectively induces donor-specific tolerance to allografts.

118 These B6 nu/nu mice maintained donor-specific tolerance to B10.A skin grafts.

119 quences in the alpha1-helical region induces donor-specific tolerance to cardiac allografts in rat re

120 men produces mixed bone marrow chimerism and donor-specific tolerance to cardiac allografts in the ra

121 Donor-specific tolerance to cardiac allografts was induc

122 hown that mixed allogeneic chimerism induces donor-specific tolerance to composite tissue allografts

123 Mixed chimerism induces donor-specific tolerance to composite tissue allotranspl

124 resent a new approach of inducing long-term, donor-specific tolerance to CTAs without recipient preco

125 etic-cell transplantation (IUHCT) can induce donor-specific tolerance to facilitate postnatal transpl

126 chronic immunosuppression, the induction of donor-specific tolerance to intestinal grafts is desirab

127 Mixed chimerism induces donor-specific tolerance to kidney and vascularized comp

128 into a lethally irradiated rat, would confer donor-specific tolerance to lung allografts.

129 Minimization of immunosuppression and donor-specific tolerance to MHC-mismatched organ grafts

130 gulatory cells are required and can transfer donor-specific tolerance to naive recipients.

131 Donor-specific tolerance to NOR islet grafts was induced

132 e development of effective methods to induce donor-specific tolerance to obviate the need for life-lo

133 ecule LFA-1 (CD11a) was sufficient to induce donor-specific tolerance to pancreatic islet allografts.

134 hocyte serum (ALS) intraperitoneally induces donor-specific tolerance to rat cardiac transplants.

135 Donor-specific tolerance to renal allografts in miniatur

136 finite allograft acceptance (>300 days), and donor-specific tolerance to secondary skin grafts.

137 finite allograft acceptance (>350 days), and donor-specific tolerance to secondary skin grafts.

138 antly enhance engraftment of HSCs and induce donor-specific tolerance to skin allografts.

139 exhibited stable multilineage chimerism and donor-specific tolerance to skin grafts and in in vitro

140 exhibited stable multilineage chimerism and donor-specific tolerance to subsequent cardiac allograft

141 amycin and IL-2/Fc fusion protein results in donor-specific tolerance to VCA, but not FTS allografts.

142 ansplantation as part of a regimen to induce donor-specific tolerance to xenogeneic organ grafts.

143 If donor-specific tolerance toward porcine antigens could b

144 haploidentical chimeric mice also displayed donor-specific tolerance upon stimulation in a one-way m

145 in solid organ xenografting may be to induce donor-specific tolerance using bone marrow transplantati

146 The induction of donor specific tolerance via bone marrow chimerism may b

147 w) subpopulation, which are able to transfer donor-specific tolerance via IL-10 and TGF-beta1-depende

148 Donor-specific tolerance was assessed with mixed lymphoc

149 Donor-specific tolerance was confirmed by acceptance of

150 Donor-specific tolerance was tested by skin grafting.

151 Donor-specific tolerance was tested by skin grafting.

152 The ultimate goal is to induce a state of donor-specific tolerance, wherein the recipient will acc

153 an achieve mixed hematopoietic chimerism and donor-specific tolerance without cytoreductive condition

154 patibility complex (MHC) barriers and induce donor-specific tolerance without immunosuppressive thera

155 are accepted across MHC barriers and induce donor-specific tolerance without immunosuppressive thera

156 ty complex (MHC) barriers in mice and induce donor-specific tolerance without requirement for immunos

157 Bone marrow chimerism induces donor-specific tolerance without the requirement for chr

158 pted the postulation that prior induction of donor-specific tolerance would attenuate or abrogate the

159 complete recipient ablation (A-->B) exhibit donor-specific tolerance, yet survival is often limited